<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210245</url>
  </required_header>
  <id_info>
    <org_study_id>282-CC-207</org_study_id>
    <nct_id>NCT04210245</nct_id>
  </id_info>
  <brief_title>Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)</brief_title>
  <official_title>Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled
      study in subjects with compensated cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will compare multiple doses of aldafermin against placebo in a compensated NASH
      cirrhosis population for 48 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in liver fibrosis of greater or equal to one stage with no worsening of NASH.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by reported and observed adverse events.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Compensated Cirrhosis</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Daily 0.3 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily 1 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily 3 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered by subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldafermin</intervention_name>
    <description>aldafermin</description>
    <arm_group_label>Daily 0.3 mg dose</arm_group_label>
    <arm_group_label>Daily 1 mg dose</arm_group_label>
    <arm_group_label>Daily 3 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for aldafermin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Liver biopsy consistent with fibrosis stage 4 (F4) cirrhosis.

          2. Compensated cirrhosis due to NASH.

          3. Total liver fat content of â‰¥ 8% as measured by MRI-PDFF.

        Key Exclusion Criteria:

          1. Other causes of liver disease including but not limited to alcoholic liver disease,
             hepatitis B, hepatitis C, autoimmune disorders, primary biliary cirrhosis,
             drug-induced hepatotoxicity, Wilson's disease, hemochromatosis, and
             alpha-1-anti-trypsin definition based on medical history and/or centralized read of
             liver histology.

          2. Evidence of drug induced steatohepatitis secondary to amiodarone, corticosteroids,
             estrogens, methotrexate, tetracycline, or other medications known to cause hepatic
             steatosis.

          3. History of hepatic decompensation including variceal bleeding, ascites, or hepatic
             encephalopathy.

          4. Model of end stage liver disease (MELD) score &gt;12.

        Other protocol-defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NGM Study Director</last_name>
    <phone>(650) 243-5555</phone>
    <email>ngm282@ngmbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 413</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 414</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 415</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 416</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 418</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 435</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 439</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 422</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 412</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 453</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 437</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 442</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 417</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 438</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 433</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 436</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 464</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 425</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 434</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 419</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 448</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 431</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 465</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 432</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 420</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 424</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 426</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 430</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 463</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 428</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 423</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 427</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 440</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 408</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 404</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 406</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 407</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 403</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 401</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 405</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 402</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 452</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 451</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 447</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 409</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 411</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 443</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 449</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 459</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 457</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 458</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 460</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 445</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Myslowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 441</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 444</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 446</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927-4807</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 429</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 455</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 456</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 454</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 450</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 410</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 466</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 461</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 462</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

